Filing Details
- Accession Number:
- 0001178913-20-001105
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-04-13 17:29:33
- Reporting Period:
- 2020-04-13
- Accepted Time:
- 2020-04-13 17:29:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1664710 | Keros Therapeutics Inc. | KROS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1321178 | Moshe Arkin | 6 Hachoshlim St. Herzelia L3 4672406 | No | No | Yes | No | |
| 1808348 | Partnership Limited Ventures Bio Arkin | 6 Hachoshlim Street Herzliya Pituach L3 4672406 | No | No | Yes | No | |
| 1808349 | Ltd. Partners Venture Bio Arkin | 6 Hachoshlim Street Herzliya Pituach L3 4672406 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-04-13 | 1,382,295 | $0.00 | 1,382,295 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-04-13 | 343,270 | $0.00 | 1,725,565 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-04-13 | 167,537 | $0.00 | 1,893,102 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2020-04-13 | 120,000 | $16.00 | 2,013,102 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2020-04-13 | 1,382,295 | $0.00 | 1,382,295 | $0.00 |
| Common Stock | Series B-1 Preferred Stock | Disposition | 2020-04-13 | 343,270 | $0.00 | 343,270 | $0.00 |
| Common Stock | Series C Preferred Stock | Disposition | 2020-04-13 | 167,537 | $0.00 | 167,537 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date.
- The securities are held by Arkin Bio Ventures Limited Partnership ("Arkin Bio"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd..
Billionaire Hedge Funds
